Ostatní
Návod 
MacroGenics, Inc.
MGNX
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.1B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
-113%
ROA
-28%
PE
-1
PS
1
Cena 1R
1-3
⌀ Cena
1.56
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
19-03-2026
Poslední dividenda
Profil
Společnost MacroGenics, Inc., biofarmaceutická společnost, vyvíjí a komercializuje protilátkovou terapii pro léčbu rakoviny ve Spojených státech. Jeho schváleným přípravkem je MARGENZA (margetuximab-cmkb), antagonista receptoru pro lidský epidermální růstový faktor 2 (HER2), indikovaný v kombinaci s chemoterapií k léčbě dospělých pacientů s metastazujícím karcinomem prsu s pozitivním HER2, kteří již byli léčeni dvěma nebo více předchozími dávkami anti-HER2. Mezi kandidátské imunoonkologické přípravky společnosti patří MGC018, konjugát protilátek (ADC), který cílí na solidní nádory s expresí B7-H3, Enoblituzumab, monoklonální protilátka cílící na B7-H3, a MGD024, což je zkoumaná bispecifická molekula CD123 × CD3 DART, která minimalizuje syndrom uvolňování cytokinů u pacientů s hematologickými malignitami. Vyvíjí se také Lorigerlimab, monoklonální protilátka, která cílí na imunitní kontrolní body PD-1 a cytotoxický protein spojený s T-lymfocyty 4; Tebotelimab, zkoumaná tetravalentní DART molekula pro PD-1 a gen 3 pro aktivaci lymfocytů; Retifanlimab, zkoumaná monoklonální protilátka cílící na metastazující karcinom dlaždicových buněk kanálového a metastazujícího nemalobuněčného karcinomu plic; a IMGC936, ADC, který cílí na ADAM9, povrchový protein, který je exprimárně exprimovaný v různých typech solidních nádorů S. Dále společnost vyvíjí MGD014 a MGD020, což je molekula DART, která se zaměřuje na obalový protein buněk infikovaných virem lidské imunodeficience a CD3 na T buňkách; teplizumab pro léčbu diabetu typu 1; a PRV- 3279, CD32B × CD79B DART molekula pro léčbu autoimunitních indikací. Spolupracuje s Incyte Corporation, Zai Lab Limited, I-Mab Biopharma a Janssen Biotech, Inc. Společnost byla založena v roce 2000 a má sídlo v Rockville, Maryland.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
341
Založení
2013-10-10
Podobné společnosti
$ 1.31
- $ 0.02
$ 2.24
+ $ 0.05
$ 1.31
+ $ 0.03
$ 1.55
+ $ 0.32
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 149.5 | 149.5 | 148.3 | 58.7 | 151.9 | 75.6 | 97.8 | 62.0 | 60.1 | 155.5 | 86.6 | 100.9 | 47.3 | 56.8 | 59.6 | 47.1 | |
| Cost of Revenues | 43.2 | 43.2 | 12.3 | 8.2 | 7.4 | 2.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | 106.3 | 106.3 | 136.0 | 50.5 | 144.6 | 73.0 | 97.8 | 62.0 | 60.1 | 155.5 | 86.6 | 100.9 | 47.3 | 56.8 | 59.6 | 47.1 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 41.2 | 72.8 | 22.2 | 13.2 | 17.7 | 110.7 | 10.8 | 9.1 | 10.7 | 10.4 | |
| Cost of Revenues | 15.5 | 13.4 | 8.9 | 5.4 | 5.5 | 42.4 | 2.8 | 2.1 | 2.1 | 0.1 | |
| Gross Profit | 25.7 | 59.5 | 13.3 | 7.8 | 12.2 | 68.3 | 8.0 | 7.0 | 8.7 | 10.3 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 166.6 | 207.0 | 214.6 | 193.2 | 195.3 | 190.8 | 147.2 | 122.1 | 98.3 | 70.2 | 46.6 | 45.4 | 41.1 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 52.2 | 58.9 | 63.0 | 42.7 | 46.1 | 40.5 | 32.7 | 29.8 | 22.8 | 15.9 | 11.1 | 10.2 | 10.9 | |
| Depreciation & Amortization | 7.2 | 7.2 | 7.5 | 9.6 | 11.9 | 11.3 | 12.0 | 10.8 | 8.3 | 7.2 | 7.6 | 2.9 | 1.8 | 1.2 | 1.0 | 1.1 | |
| Total Operating Expenses | 179.2 | 179.2 | 246.6 | 217.2 | 266.0 | 275.8 | 228.8 | 239.2 | 231.3 | 177.7 | 146.6 | 121.0 | 85.6 | 56.4 | 51.4 | 41.8 | |
| Operating Income | -72.8 | -72.8 | -110.6 | -168.2 | -121.4 | -202.8 | -131.1 | -177.2 | -171.2 | -22.1 | -60.0 | -20.2 | -38.3 | 0.4 | 8.2 | 5.2 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 45.5 | 30.1 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.6 | 12.4 | ||
| Depreciation & Amortization | 1.7 | 1.8 | 1.9 | 1.8 | 2.1 | 1.8 | 1.8 | 1.8 | 1.9 | 2.0 | ||
| Total Operating Expenses | 37.8 | 40.8 | 50.1 | 50.4 | 65.1 | 14.1 | 66.2 | 60.7 | 58.0 | 45.8 | ||
| Operating Income | -12.1 | 18.6 | -36.8 | -42.6 | -52.8 | 54.2 | -58.2 | -53.8 | -49.4 | -35.5 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 3.4 | 3.4 | 9.4 | 9.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Interest Expense | 8.5 | 8.5 | 1.1 | 1.4 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Expense | -2.5 | -2.5 | 44.6 | 159.2 | 1.7 | 0.7 | 1.3 | 25.4 | -0.2 | 2.5 | 1.5 | 0.0 | 0.0 | -0.6 | 0.2 | 1.5 | |
| IBT | -75.3 | -75.3 | -66.0 | -9.1 | -119.8 | -202.1 | -129.7 | -151.8 | -171.5 | -19.6 | -58.5 | -20.1 | -38.3 | -0.3 | 8.4 | 6.7 | |
| Income Tax Expense | -0.7 | -0.7 | 0.9 | 0.0 | 0.3 | -11.3 | -12.0 | 0.0 | -0.2 | -7.2 | -7.6 | 0.0 | -1.8 | 0.0 | 0.0 | 0.0 | |
| Net Income | -74.6 | -74.6 | -67.0 | -9.1 | -120.0 | -190.9 | -117.8 | -151.8 | -171.5 | -19.6 | -58.5 | -20.1 | -38.3 | -0.3 | 8.4 | 6.7 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | -1.2 | 1.5 | 1.4 | 1.7 | 2.1 | 2.1 | 2.5 | 2.7 | 3.3 | 3.1 | ||
| Interest Expense | 4.3 | 3.3 | 0.8 | 0.1 | 0.0 | 0.0 | 0.0 | 1.1 | 0.0 | 0.0 | ||
| Other Expense | -2.8 | -1.8 | 0.6 | 1.6 | 38.4 | 2.1 | 2.5 | 1.6 | 3.3 | 53.1 | ||
| IBT | -14.9 | 16.8 | -36.1 | -41.0 | -14.5 | 56.3 | -55.7 | -52.2 | -46.1 | 17.6 | ||
| Income Tax Expense | -0.8 | 0.0 | 0.1 | 0.0 | 0.9 | 0.0 | 0.0 | 0.0 | 3.2 | -2.0 | ||
| Net Income | -14.2 | 16.8 | -36.3 | -41.0 | -15.4 | 56.3 | -55.7 | -52.2 | -46.1 | 17.6 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-0.15 | $-1.95 | $-3.18 | $-2.25 | $-3.16 | $-4.19 | $-0.54 | $-1.69 | $-0.63 | $-1.40 | $-0.04 | $0.46 | $0.37 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-0.15 | $-1.95 | $-3.18 | $-2.25 | $-3.16 | $-4.19 | $-0.54 | $-1.69 | $-0.63 | $-1.40 | $-0.04 | $0.46 | $0.37 | |
| Shares Outstanding | 63.2 | 63.2 | 62.6 | 61.9 | 61.4 | 59.9 | 52.4 | 48.1 | 40.9 | 36.1 | 34.7 | 31.8 | 27.4 | 6.8 | 18.1 | 18.1 | |
| Diluted Shares Outstanding | 63.2 | 63.2 | 62.6 | 61.9 | 61.4 | 59.9 | 52.4 | 48.1 | 40.9 | 36.1 | 34.7 | 31.8 | 27.4 | 6.8 | 18.1 | 18.1 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.74 | $0.28 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.74 | $0.28 | ||
| Shares Outstanding | 63.2 | 63.2 | 63.1 | 63.0 | 62.6 | 62.7 | 62.7 | 62.3 | 62.1 | 62.0 | ||
| Diluted Shares Outstanding | 63.2 | 63.3 | 63.1 | 63.0 | 62.6 | 62.9 | 62.7 | 62.3 | 62.1 | 62.2 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 83.9 | 182.8 | 101.0 | 108.9 | 123.5 | 181.1 | 126.5 | 220.1 | 211.7 | 84.1 | 196.2 | 157.6 | 116.5 | 47.7 | 55.2 | |
| Short Term Investments | 56.4 | 18.8 | 128.8 | 45.5 | 120.1 | 91.4 | 89.3 | 12.7 | 93.4 | 192.9 | 142.9 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 140.4 | 201.7 | 229.8 | 154.3 | 243.6 | 272.5 | 215.8 | 232.9 | 305.1 | 285.0 | 339.0 | 157.6 | 116.5 | 47.7 | 55.2 | |
| Accounts Receivable | 6.2 | 4.3 | 10.4 | 56.2 | 10.4 | 23.1 | 12.7 | 29.6 | 13.6 | 2.8 | 1.2 | 2.9 | 2.0 | 2.0 | 3.4 | |
| Inventory | 1.1 | 0.0 | 1.2 | 1.5 | 4.4 | 0.0 | 0.0 | 0.0 | 0.0 | -8.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 9.3 | 11.5 | 9.9 | 10.2 | 21.2 | 17.0 | 11.3 | 6.7 | 3.5 | 4.2 | 2.1 | 4.2 | 1.0 | 0.1 | 0.0 | |
| Total Current Assets | 157.0 | 217.5 | 251.3 | 222.2 | 279.6 | 312.6 | 239.8 | 269.1 | 322.3 | 283.9 | 342.4 | 164.7 | 119.5 | 49.9 | 58.7 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 80.1 | 130.7 | 145.6 | 182.8 | 179.6 | 83.9 | 80.4 | 101.0 | 89.9 | 108.8 | |
| Short Term Investments | 66.3 | 45.8 | 8.6 | 18.8 | 20.7 | 56.4 | 103.9 | 128.8 | 166.5 | 131.6 | |
| Total Cash & ST Investments | 146.4 | 176.5 | 154.1 | 201.7 | 200.4 | 140.4 | 184.2 | 229.8 | 256.4 | 240.3 | |
| Accounts Receivable | 69.2 | 12.5 | 10.5 | 4.3 | 8.8 | 6.2 | 7.2 | 10.4 | 25.3 | 6.4 | |
| Inventory | 8.8 | 9.3 | 9.4 | 0.0 | 3.2 | 1.1 | 1.2 | 1.2 | 1.1 | 1.4 | |
| Other Current Assets | 7.7 | 6.7 | 8.0 | 11.5 | 9.8 | 9.3 | 9.9 | 9.9 | 8.5 | 6.5 | |
| Total Current Assets | 232.1 | 204.9 | 182.1 | 217.5 | 222.2 | 157.0 | 202.6 | 251.3 | 291.3 | 240.3 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 43.0 | 42.6 | 45.7 | 56.9 | 37.7 | 42.2 | 48.2 | 56.7 | 50.0 | 18.0 | 14.8 | 6.8 | 5.0 | 3.3 | 3.3 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 1.2 | 10.5 | 1.4 | 1.4 | 18.0 | 23.9 | 24.5 | 6.3 | 1.6 | 1.4 | 2.0 | 2.4 | 1.3 | 0.6 | 0.7 | |
| Total Long-Term Assets | 44.2 | 53.1 | 47.1 | 58.3 | 55.7 | 66.1 | 72.7 | 63.0 | 51.6 | 27.3 | 16.9 | 9.1 | 6.3 | 3.8 | 4.0 | |
| Total Assets | 201.1 | 261.7 | 298.4 | 280.5 | 335.2 | 378.7 | 312.5 | 332.1 | 373.9 | 311.3 | 359.3 | 173.9 | 125.8 | 53.7 | 62.7 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 37.3 | 39.1 | 41.0 | 42.6 | 41.1 | 43.0 | 44.5 | 45.7 | 47.3 | 49.6 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 1.4 | 1.4 | 1.5 | 10.5 | 1.2 | 1.2 | 1.2 | 1.4 | 1.4 | 15.7 | |
| Total Long-Term Assets | 38.7 | 40.5 | 42.5 | 53.1 | 42.3 | 44.2 | 45.7 | 55.5 | 48.7 | 65.3 | |
| Total Assets | 270.8 | 245.4 | 224.6 | 261.7 | 264.5 | 201.1 | 248.3 | 306.8 | 340.0 | 305.7 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 5.2 | 5.0 | 6.4 | 4.9 | 15.5 | 8.0 | 4.3 | 4.0 | 2.5 | 4.0 | 3.0 | 1.7 | 3.2 | 3.7 | 11.1 | |
| Short-Term Debt | 4.4 | 4.9 | 7.6 | 4.7 | 4.7 | 4.0 | 3.0 | 34.0 | 0.3 | 1.6 | 2.0 | 1.6 | 1,438.7 | 1.2 | 1.1 | |
| Other Current Liabilities | 24.4 | 29.3 | 16.7 | -30.5 | 33.8 | 27.3 | 27.1 | 0.2 | 39.8 | 17.5 | 12.4 | 9.5 | -1,433.4 | 0.6 | 0.5 | |
| Current Liabilities | 57.9 | 55.5 | 56.1 | 48.6 | 74.6 | 50.7 | 45.2 | 59.9 | 49.8 | 27.3 | 23.3 | 27.1 | 28.8 | 29.7 | 44.3 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 5.9 | 4.7 | 6.6 | 5.0 | 6.6 | 5.2 | 10.7 | 6.4 | 3.3 | 3.8 | |
| Short-Term Debt | 5.1 | 5.1 | 5.4 | 4.9 | 4.7 | 4.4 | 4.1 | 7.6 | 7.9 | 4.2 | |
| Other Current Liabilities | 23.1 | 21.3 | 27.8 | 29.3 | 24.6 | 24.4 | 18.1 | 16.7 | 17.6 | 27.5 | |
| Current Liabilities | 44.5 | 39.0 | 55.4 | 55.5 | 59.3 | 57.9 | 55.8 | 56.1 | 51.3 | 68.2 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 29.7 | 32.6 | 30.2 | 30.1 | 20.8 | 25.3 | 27.6 | 0.0 | 0.0 | 0.3 | 2.7 | 6.4 | 8,006.4 | 0.0 | 0.0 | |
| Capital Leases | 29.7 | 37.5 | 34.0 | 34.8 | 25.5 | 29.2 | 30.6 | 0.0 | 0.3 | 1.9 | 4.7 | 8.0 | 9,445.2 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 8.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 4.6 | -3.7 | -8,003.5 | 0.0 | 0.0 | |
| Total Liabilities | 143.3 | 145.6 | 145.8 | 138.5 | 95.6 | 82.9 | 81.9 | 89.3 | 74.6 | 42.5 | 45.9 | 52.6 | 46.9 | 62.0 | 80.2 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 31.9 | 102.4 | 32.1 | 32.6 | 29.4 | 29.7 | 29.9 | 30.2 | 30.2 | 30.2 | |
| Capital Leases | 37.0 | 37.2 | 37.5 | 37.5 | 34.1 | 34.1 | 29.9 | 30.2 | 34.1 | 34.3 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 8.9 | 0.0 | 0.0 | 0.0 | 8.4 | 0.0 | -23.1 | |
| Total Liabilities | 203.8 | 198.8 | 145.4 | 145.6 | 144.4 | 143.3 | 142.1 | 154.2 | 146.0 | 134.1 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.0 | 0.0 | |
| Retained Earnings | -1,210.6 | -1,169.7 | -1,102.8 | -1,093.7 | -973.9 | -771.8 | -642.1 | -490.3 | -312.3 | -292.7 | -234.2 | -214.0 | -175.7 | -175.5 | -183.8 | |
| Comprehensive Income | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | 0.0 | -17.4 | -15.5 | -14.3 | -13.4 | |
| Total Common Equity | 57.8 | 116.1 | 152.6 | 142.0 | 239.6 | 295.9 | 230.6 | 242.9 | 299.2 | 268.8 | 313.3 | 121.3 | 78.9 | -8.2 | -17.5 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | |
| Retained Earnings | -1,230.2 | -1,247.0 | -1,210.8 | -1,169.7 | -1,154.3 | -1,210.6 | -1,154.9 | -1,102.8 | -1,056.7 | -1,074.2 | |
| Comprehensive Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | |
| Total Common Equity | 67.0 | 46.6 | 79.1 | 116.1 | 120.1 | 57.8 | 106.2 | 152.6 | 194.0 | 171.5 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 34.1 | 37.5 | 34.0 | 34.8 | 25.5 | 29.2 | 30.6 | 0.0 | 0.3 | 1.9 | 4.7 | 8.0 | 1.4 | 0.0 | 0.0 | |
| Book Value | 57.8 | 116.1 | 152.6 | 142.0 | 239.6 | 295.9 | 230.6 | 242.9 | 299.2 | 268.8 | 313.3 | 121.3 | 78.9 | -8.2 | -17.5 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 67.0 | 46.6 | 79.1 | 116.1 | 120.1 | 57.8 | 106.2 | 152.6 | 194.0 | 171.5 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -136.4 | -74.6 | -67.0 | -9.1 | -119.8 | -202.1 | -129.7 | -151.8 | -171.5 | -19.6 | -58.5 | -20.1 | -38.3 | -0.3 | 8.4 | 6.7 | |
| Depreciation & Amortization | 7.5 | 5.5 | 7.5 | 9.6 | 11.9 | 11.3 | 12.0 | 10.8 | 8.3 | 7.2 | 7.6 | 2.9 | 1.8 | 1.2 | 1.0 | 1.1 | |
| Stock-Based Compensation | 21.4 | 14.3 | 29.4 | 18.4 | 20.4 | 23.1 | 20.7 | 19.6 | 16.5 | 14.7 | 12.2 | 7.8 | 3.2 | 0.9 | 0.8 | 2.3 | |
| Change Working Capital | 7.7 | -28.3 | 1.4 | 53.3 | -2.8 | 20.3 | -14.5 | -12.9 | -6.6 | 12.1 | -4.9 | -4.2 | 0.5 | -16.6 | -16.6 | -2.0 | |
| Change In Accounts Receivable | 0.2 | -9.1 | 6.1 | 45.9 | -45.8 | 12.7 | -10.3 | 16.8 | -15.9 | -10.9 | -1.5 | 1.7 | -0.9 | 0.0 | 1.4 | 12.6 | |
| Change In Accounts Payable | 1.1 | -0.3 | -1.5 | 1.3 | -10.9 | 7.1 | 3.7 | 0.8 | 1.6 | -1.5 | 2.2 | -0.2 | -1.5 | -0.6 | -7.3 | -10.3 | |
| Change In Inventories | 0.3 | -7.9 | -2.2 | 0.2 | 0.1 | -6.4 | 0.6 | -9.6 | -4.6 | 11.8 | -0.3 | 1.5 | -0.3 | 0.5 | -0.4 | -0.2 | |
| Other Non-cash Items | -44.8 | 2.1 | -39.8 | -150.5 | 3.3 | 2.0 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | -0.2 | -1.5 | |
| Cash from Operations | -153.4 | 0.0 | 0.0 | -78.2 | -87.0 | -143.8 | -111.9 | -134.3 | -153.2 | 14.4 | -43.7 | -13.7 | -32.8 | -14.2 | -6.6 | 6.8 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -14.2 | 16.8 | -36.3 | -41.0 | -15.4 | 56.3 | -55.7 | -52.2 | -46.1 | 17.6 | |
| Depreciation & Amortization | 1.6 | 1.8 | 1.9 | 1.8 | 2.1 | 1.8 | 1.8 | 1.8 | 1.9 | 2.0 | |
| Stock-Based Compensation | 2.7 | 3.5 | 3.7 | 4.4 | 0.0 | 0.0 | 6.7 | 0.0 | 4.4 | 4.8 | |
| Change Working Capital | 53.1 | -52.2 | -17.0 | -12.2 | 2.6 | -4.1 | 3.0 | -0.1 | 12.7 | -7.9 | |
| Change In Accounts Receivable | 55.9 | -56.7 | -2.0 | -6.2 | 4.4 | -2.6 | 1.0 | 3.1 | 14.9 | -18.9 | |
| Change In Accounts Payable | -1.2 | 1.3 | -1.6 | 1.3 | -1.7 | 1.4 | -5.4 | 4.2 | 2.9 | -0.5 | |
| Change In Inventories | 0.8 | 0.5 | 0.2 | -9.4 | -0.2 | -2.1 | 0.1 | 0.0 | -0.2 | 0.4 | |
| Other Non-cash Items | -0.2 | -0.1 | 0.7 | 0.2 | -27.7 | 6.1 | -0.3 | 4.9 | -10.5 | -49.8 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -28.0 | -35.2 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -3.6 | -1.9 | -3.7 | -1.8 | -3.6 | -6.2 | -5.9 | -4.3 | -25.0 | -29.4 | -11.4 | -9.2 | -3.6 | -3.0 | -0.9 | -0.5 | |
| Acquisitions | 28.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | -150.1 | -208.3 | -77.2 | -239.7 | -120.6 | -231.2 | -223.7 | -264.4 | -132.8 | -135.1 | -347.8 | -142.9 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 231.2 | 96.1 | 190.0 | 161.3 | 194.9 | 200.8 | 221.9 | 189.3 | 214.3 | 242.4 | 288.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | -28.4 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Investing | 77.5 | 0.0 | 0.0 | -80.1 | 70.7 | -36.6 | -7.8 | -79.4 | 56.6 | 77.9 | -70.2 | -152.1 | -3.6 | -3.0 | -0.9 | -0.5 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.2 | -0.4 | -0.7 | -0.5 | -0.6 | -0.6 | -1.0 | -1.5 | -0.6 | -0.5 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 40.0 | 0.1 | 0.0 | 0.0 | 28.4 | 0.0 | |
| Investments | -88.8 | -66.1 | -45.5 | -7.9 | -13.8 | -4.9 | -8.0 | -50.5 | -22.5 | -69.2 | |
| Sales of Investment | 23.1 | 46.1 | 8.6 | 18.3 | 15.9 | 41.0 | 56.4 | 76.8 | 61.9 | 36.1 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -28.4 | 0.0 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 38.8 | -33.5 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | -0.3 | 37.5 | 3.5 | -0.9 | 9.4 | -3.8 | -1.3 | 30.6 | -0.3 | -1.6 | -2.8 | -3.3 | 6.6 | 1.4 | 0.0 | 0.0 | |
| Issuance of Common Stock | 3.6 | 0.0 | 0.0 | 0.6 | 1.1 | 117.8 | 170.5 | 118.7 | 103.3 | 34.2 | 0.0 | 203.5 | 76.7 | 85.9 | 0.0 | 0.1 | |
| Repurchase of Common Stock | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.0 | 0.0 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 47.5 | 0.0 | 0.0 | 149.7 | 0.6 | 5.0 | 5.9 | 1.3 | 2.0 | 1.1 | 1.9 | 0.9 | 0.7 | 0.0 | 0.0 | 12.0 | |
| Cash from Financing | 51.1 | 0.0 | 0.0 | 150.4 | 1.7 | 122.8 | 174.3 | 120.0 | 105.0 | 35.3 | 1.9 | 204.3 | 77.4 | 85.9 | 0.0 | 12.1 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 37.0 | -70.5 | 70.0 | 0.0 | 3.4 | 0.0 | 0.0 | 0.0 | -0.1 | -0.2 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.1 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 49.9 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 49.9 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -24.8 | -125.6 | 81.9 | -7.9 | -14.6 | -57.7 | 54.7 | -93.7 | 8.4 | 127.6 | -112.1 | 38.6 | 41.1 | 68.7 | -7.5 | 18.3 | |
| Closing Cash Balance | 83.9 | 57.2 | 182.8 | 101.0 | 108.9 | 123.5 | 181.1 | 126.5 | 220.1 | 211.7 | 84.1 | 196.2 | 157.6 | 116.5 | 47.7 | 55.2 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -22.9 | -50.6 | -14.9 | -37.3 | 3.2 | 95.7 | 3.6 | -20.6 | 11.1 | -18.9 | |
| Closing Cash Balance | 57.2 | 80.1 | 130.7 | 145.6 | 182.8 | 179.6 | 83.9 | 80.4 | 101.0 | 89.9 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -157.0 | -83.0 | -72.1 | -80.0 | -90.6 | -150.0 | -117.8 | -138.6 | -178.2 | -15.0 | -55.1 | -22.9 | -36.3 | -17.1 | -7.5 | 6.3 | |
| Real Free Cash Flow | -178.4 | -97.2 | -101.5 | -98.3 | -111.0 | -173.2 | -138.5 | -158.1 | -194.7 | -29.7 | -67.2 | -30.7 | -39.6 | -18.0 | -8.4 | 3.9 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 42.8 | -30.6 | -47.7 | -47.4 | -39.0 | 59.6 | -45.5 | -47.1 | -28.7 | -35.7 | |
| Real Free Cash Flow | 40.1 | -34.2 | -51.4 | -51.8 | -39.0 | 59.6 | -52.2 | -47.1 | -33.0 | -40.5 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -1.4 | -3131.5 | -1.4 |
| P/S | 0.9 | 10.7 | 9.4 |
| P/B | 1.6 | 0.3 | 5.2 |
| P/FCF | -0.6 | -13.1 | -1.5 |
| Market cap | $0.1 | $53.9 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 13.7 % | 56332.5 % | 0 % |
| Debt to Income | -49.6 % | 2811868.1 % | 0 % |
| Debt to Free cash flow | -38.1 % | -1387.7 % | 0 % |
| Interest expense percentage | -11.7 % | -0.1 % | 0 % |
| Current ratio | 5.2 | 6.3 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -111.4 % | -44.1 % | 0 % |
| ROA | -27.6 % | -26.5 % | 0 % |
| CapEx to Revenue | 1.8 % | 13 % | 0 % |
| RaD to Revenue | 0 % | 208.7 % | 0 % |
| ROEM | 438,416.4 | 234617.3 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 73.7 % | 96.9 % | 0 % |
| Operating margin | -90.1 % | -167.4 % | 0 % |
| Net margin | -60.2 % | -142.4 % | 0 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | -0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 63.3 mil | 44.7 mil |
| Employee count | 0.3 tis | 0.3 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
